ALK-Abelló A/S
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more
Market Cap & Net Worth: ALK-Abelló A/S (AKBLF)
ALK-Abelló A/S (PINK:AKBLF) has a market capitalization of $4.01 Billion ($4.01 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #4266 globally and #2689 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALK-Abelló A/S's stock price $19.90 by its total outstanding shares 201305917 (201.31 Million).
ALK-Abelló A/S Market Cap History: 2015 to 2025
ALK-Abelló A/S's market capitalization history from 2015 to 2025. Data shows change from $25.47 Billion to $4.01 Billion (-17.31% CAGR).
ALK-Abelló A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALK-Abelló A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.80x
ALK-Abelló A/S's market cap is 0.80 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
5.45x
ALK-Abelló A/S's market cap is 5.45 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $25.47 Billion | $2.57 Billion | $344.00 Million | 9.92x | 74.05x |
| 2016 | $26.47 Billion | $3.00 Billion | $270.00 Million | 8.81x | 98.05x |
| 2017 | $31.91 Billion | $2.91 Billion | -$158.00 Million | 10.96x | N/A |
| 2018 | $37.24 Billion | $2.92 Billion | -$170.00 Million | 12.78x | N/A |
| 2019 | $50.32 Billion | $3.27 Billion | -$50.00 Million | 15.37x | N/A |
| 2020 | $52.24 Billion | $3.49 Billion | $25.00 Million | 14.96x | 2089.56x |
| 2021 | $103.07 Billion | $3.92 Billion | $219.00 Million | 26.32x | 470.63x |
| 2022 | $2.82 Billion | $4.51 Billion | $335.00 Million | 0.62x | 8.41x |
| 2023 | $2.67 Billion | $4.82 Billion | $486.00 Million | 0.55x | 5.49x |
| 2024 | $4.44 Billion | $5.54 Billion | $815.00 Million | 0.80x | 5.45x |
Competitor Companies of AKBLF by Market Capitalization
Companies near ALK-Abelló A/S in the global market cap rankings as of March 18, 2026.
Key companies related to ALK-Abelló A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ALK-Abelló A/S Historical Marketcap From 2015 to 2025
Between 2015 and today, ALK-Abelló A/S's market cap moved from $25.47 Billion to $ 4.01 Billion, with a yearly change of -17.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.01 Billion | -9.75% |
| 2024 | $4.44 Billion | +66.42% |
| 2023 | $2.67 Billion | -5.36% |
| 2022 | $2.82 Billion | -97.27% |
| 2021 | $103.07 Billion | +97.30% |
| 2020 | $52.24 Billion | +3.82% |
| 2019 | $50.32 Billion | +35.11% |
| 2018 | $37.24 Billion | +16.72% |
| 2017 | $31.91 Billion | +20.52% |
| 2016 | $26.47 Billion | +3.93% |
| 2015 | $25.47 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of ALK-Abelló A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.01 Billion USD |
| MoneyControl | $4.01 Billion USD |
| MarketWatch | $4.01 Billion USD |
| marketcap.company | $4.01 Billion USD |
| Reuters | $4.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.